Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 11c Erlotinib
2. 11c-erlotinib
3. 358,774, Cp
4. 358774, Cp
5. Cp 358,774
6. Cp 358774
7. Cp-358,774
8. Cp-358774
9. Cp358,774
10. Cp358774
11. Erlotinib
12. Erlotinib Hcl
13. Hcl, Erlotinib
14. Hydrochloride, Erlotinib
15. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
16. Osi 774
17. Osi-774
18. Osi774
19. Tarceva
1. 183319-69-9
2. Erlotinib Hcl
3. Tarceva
4. Osi-774
5. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Hydrochloride
6. Osi 774
7. Erlotinib (hydrochloride)
8. Cp-358774
9. Cp 358774
10. Erlotinib, Hydrochloride Salt
11. Tarceva (erlotinib Hydrochloride)
12. Nsc 718781
13. Cp-358,774-01
14. Da87705x9k
15. 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline Hydrochloride
16. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride
17. Cp-358
18. 4-quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, Hydrochloride (1:1)
19. Nsc-718781
20. 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline Hcl
21. 183319-69-9 (hcl)
22. 4-(m-ethynylanilino)-6,7-bis(2-methoxyethoxy)quinazoline Monohydrochloride
23. Cp-358774-01
24. 4-quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, Monohydrochloride
25. [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine Hydrochloride
26. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride.
27. Chebi:53509
28. Osi-744
29. Smr002529980
30. Erlotinib Hydrochloride [usan]
31. Nsc718781
32. 183319-69-9 Pound Not183321-74-6
33. Erlotinib Hcl (osi-744)
34. Unii-da87705x9k
35. Erlotinib, Hcl
36. Erlotinib Hcl Salt
37. Erlotinib Hydrochloride [usan:inn]
38. Tarceva (osi)
39. Tarceva Hydrochloride
40. Mfcd07781272
41. Erlotonib Hydrochloride
42. Erlotinib Hydrochlroide
43. Erlotinib(osi-744)
44. Mls003899192
45. Mls004774139
46. Chembl1079742
47. Nsc 718781) Hcl
48. Dtxsid10171412
49. Ex-a064
50. Erlotinib Hydrochloride (tarceva)
51. Bcpp000238
52. Bcp02600
53. Erlotinib Hydrochloride [mi]
54. Ac-400
55. Erlotinib Hydrochloride [jan]
56. S1023
57. Akos015849087
58. Bcp9000658
59. Ccg-269002
60. Cs-0123
61. Erlotinib Hydrochloride [mart.]
62. Ks-1202
63. Pb30965
64. Sb16917
65. Erlotinib Hydrochloride [usp-rs]
66. Erlotinib Hydrochloride [who-dd]
67. Ro-50-8231
68. Be164421
69. Bp-30224
70. Hy-12008
71. (cp358774
72. Db-011534
73. Am20090622
74. Erlotinib Hydrochloride [orange Book]
75. Ft-0651479
76. Ec-000.2313
77. E-4007
78. 319e699
79. Q27124083
80. F0001-2385
81. Erlotinib Hydrochloride Is Known As A Egfr Kinase Inhibitor.
82. Erlotinib Hydrochloride,cp-358774, Osi-774, Nsc 718781
83. 6,7-bis-(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline Hydrochloride
84. [6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl- Phenyl)amine Hydrochloride
85. N-(3-ethenylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Hydrochloride
86. N-(3-ethynylphenyl)-6,7-bis(1-methoxyethoxy)-4-quinazolinamine Hydrochloride
87. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Monohydrochloride
88. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-quinazolin-4-amine Hydrochloride
Molecular Weight | 429.9 g/mol |
---|---|
Molecular Formula | C22H24ClN3O4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 11 |
Exact Mass | 429.1455339 g/mol |
Monoisotopic Mass | 429.1455339 g/mol |
Topological Polar Surface Area | 74.7 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 525 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Erlotinib hydrochloride |
Drug Label | TARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti... |
Active Ingredient | Erlotinib hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 150mg base; eq 25mg base |
Market Status | Prescription |
Company | Mylan Pharms |
2 of 4 | |
---|---|
Drug Name | Tarceva |
PubMed Health | Erlotinib (By mouth) |
Drug Classes | Antineoplastic Agent, Immunological Agent |
Drug Label | TARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti... |
Active Ingredient | Erlotinib hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 150mg base; eq 25mg base |
Market Status | Prescription |
Company | Osi Pharms |
3 of 4 | |
---|---|
Drug Name | Erlotinib hydrochloride |
Drug Label | TARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti... |
Active Ingredient | Erlotinib hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 150mg base; eq 25mg base |
Market Status | Prescription |
Company | Mylan Pharms |
4 of 4 | |
---|---|
Drug Name | Tarceva |
PubMed Health | Erlotinib (By mouth) |
Drug Classes | Antineoplastic Agent, Immunological Agent |
Drug Label | TARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti... |
Active Ingredient | Erlotinib hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 150mg base; eq 25mg base |
Market Status | Prescription |
Company | Osi Pharms |
* Non-small cell lung cancer (NSCLC):
Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.
Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.
When prescribing Tarceva, factors associated with prolonged survival should be taken into account.
No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours.
* Pancreatic cancer :
Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer .
When prescribing Tarceva, factors associated with prolonged survival should be taken into account.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01EB02
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
22
PharmaCompass offers a list of Erlotinib Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Erlotinib Hydrochloride manufacturer or Erlotinib Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Erlotinib Hydrochloride manufacturer or Erlotinib Hydrochloride supplier.
PharmaCompass also assists you with knowing the Erlotinib Hydrochloride API Price utilized in the formulation of products. Erlotinib Hydrochloride API Price is not always fixed or binding as the Erlotinib Hydrochloride Price is obtained through a variety of data sources. The Erlotinib Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A erlotinib HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of erlotinib HCl, including repackagers and relabelers. The FDA regulates erlotinib HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. erlotinib HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of erlotinib HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A erlotinib HCl supplier is an individual or a company that provides erlotinib HCl active pharmaceutical ingredient (API) or erlotinib HCl finished formulations upon request. The erlotinib HCl suppliers may include erlotinib HCl API manufacturers, exporters, distributors and traders.
click here to find a list of erlotinib HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A erlotinib HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of erlotinib HCl active pharmaceutical ingredient (API) in detail. Different forms of erlotinib HCl DMFs exist exist since differing nations have different regulations, such as erlotinib HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A erlotinib HCl DMF submitted to regulatory agencies in the US is known as a USDMF. erlotinib HCl USDMF includes data on erlotinib HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The erlotinib HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of erlotinib HCl suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The erlotinib HCl Drug Master File in Japan (erlotinib HCl JDMF) empowers erlotinib HCl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the erlotinib HCl JDMF during the approval evaluation for pharmaceutical products. At the time of erlotinib HCl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of erlotinib HCl suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a erlotinib HCl Drug Master File in Korea (erlotinib HCl KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of erlotinib HCl. The MFDS reviews the erlotinib HCl KDMF as part of the drug registration process and uses the information provided in the erlotinib HCl KDMF to evaluate the safety and efficacy of the drug.
After submitting a erlotinib HCl KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their erlotinib HCl API can apply through the Korea Drug Master File (KDMF).
click here to find a list of erlotinib HCl suppliers with KDMF on PharmaCompass.
A erlotinib HCl written confirmation (erlotinib HCl WC) is an official document issued by a regulatory agency to a erlotinib HCl manufacturer, verifying that the manufacturing facility of a erlotinib HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting erlotinib HCl APIs or erlotinib HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a erlotinib HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of erlotinib HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing erlotinib HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for erlotinib HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture erlotinib HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain erlotinib HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a erlotinib HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of erlotinib HCl suppliers with NDC on PharmaCompass.
erlotinib HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of erlotinib HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right erlotinib HCl GMP manufacturer or erlotinib HCl GMP API supplier for your needs.
A erlotinib HCl CoA (Certificate of Analysis) is a formal document that attests to erlotinib HCl's compliance with erlotinib HCl specifications and serves as a tool for batch-level quality control.
erlotinib HCl CoA mostly includes findings from lab analyses of a specific batch. For each erlotinib HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
erlotinib HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (erlotinib HCl EP), erlotinib HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (erlotinib HCl USP).